Forex Again Lifts Major Japanese Firms’ Results
Major Japanese firms report a generally positive quarter helped by forex effects, leading Takeda and Shionogi to revise upwards their guidance for the full fiscal year.
Scrip - November 5, 2026

TCT 2026: Edwards Pushes TAVR Into Moderate Aortic Stenosis; Medtronic Touts Renal Denervation Data
Edwards touted PROGRESS data showing SAPIEN 3 TAVR cut heart failure events in moderate AS, while EARLY TAVR economics showed cost parity. Medtronic reported significant six-month BP reductions for Symplicity Spyral in SPYRAL AFFIRM.
Medtech Insight - November 4, 2026

FDA Cites Next Medical For Contamination Controls And Unapproved Ultrasound Gel Changes
The FDA issued a warning letter to Next Medical Products Company, citing inadequate contamination controls, failures to validate changes to its ultrasound gel formulation, and failure to report a correction involving contaminated products, and failed to obtain a new 510(k) for a reformulated gel.
Medtech Insight - November 4, 2026

Philips’s Diagnosis & Treatment Orders Jump Close To 20%, But Ultrasound Delays Keep Sales Flat
Diagnosis & Treatment orders rose close to 20% as Philips’s imaging rebuild gained traction, but ultrasound shipment delays and weaker China sales left segment revenue flat.
Medtech Insight - November 4, 2026

TCT 2026: Abbott’s Amulet 360 Hits 96.3% Complete LAA Closure at One Year in Pivotal VERITAS Study
Abbott reported positive one-year results from the VERITAS study of its Amulet 360 left atrial appendage (LAA) closure device at TCT 2026. Complete closure was seen in 96.3% of patients, with a 1.8% rate of ischemic stroke or systemic embolism. The device has a CE Mark and FDA approval is expected.
Medtech Insight - November 4, 2026

Toothpaste, Hair Regrowth Recalls Hit US Market; EU Panel Sets Limits For Two Fragrance Ingredients
Recent beauty regulatory news includes US recalls of more than four million tubes of toothpaste and about 11,000 hair regrowth products, while an EU scientific committee found two fragrance ingredients safe at set limits.
HBW Insight - November 5, 2026

Teva Builds On Samsung Bioepis Alliance With Another Two Products As Biosimilars Exceed Expectations
As Teva announced a significant expansion of its biosimilars alliance with Samsung Bioepis, the firm also reported that it was on track to hit its $800m biosimilars sales target for 2027 a year early, helping to partly offset a generics slide due to lower US lenalidomide turnover.
Generics Bulletin - November 4, 2026

FDA Tentative Approval Clears Path For Dr Reddy’s Launch Of Generic Lenacapavir In 120 Countries
With the FDA’s tentative approval now secured, first supplies of Dr Reddy’s generic lenacapavir long-acting injection for HIV prevention are expected to reach LMICs before the end of 2026, while broader rollout is expected next year.
Generics Bulletin - November 4, 2026

Mapping Out Big Pharma’s Obesity Shopping List Beyond The Incretin Rush
With independent late-stage incretin programs thinning, big pharma could look at mechanisms that complement existing weight loss drugs or address their limitations.
In Vivo - November 3, 2026

Strategic Intent: How Circio Rebuilt Itself Around Circular RNA
Most biotech companies spend their time creating value. Far fewer have to figure out how to rebuild it. Erik Wiklund, CEO of Norwegian biotech Circio, has done both.
In Vivo - November 3, 2026